NextCure, Inc. (NXTC) Form 8-K — Nov 20, 2026
NextCure received a Nasdaq notice on November 16, 2026 stating it is not in compliance with the Global Select Market minimum stockholders' equity requirement, reporting equity of $5.5 million versus the required $10.0 million minimum. The company has until January 4, 2027 to submit a compliance plan, but believes its proposed merger with Avere Therapeutics, expected to close in mid-December 2026 pending stockholder approval, would restore compliance and may eliminate the need for a plan.
Key figures
- Stockholders Equity
- 5503000
- Grace period days
- 45
- Compliance plan deadline
- January 4, 2027
- Minimum stockholders equity required
- $10.0 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.